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Background/aim: The objectives were to define the distribution of rheumatic diseases in patients with erythrocyte sedimentation rate
(ESR) ≥ 100 mm/h and to find variables that can differentiate main study groups from others.
Materials and methods: Charts of patients admitted with ESR ≥ 100 mm/h between 2015 and 2020 were reviewed. Patients were divided
into four diagnostic groups based on etiology: infection (without a rheumatic diagnosis), oncologic (without a rheumatic diagnosis),
rheumatic, and no definitive diagnosis. Patients with the rheumatic diagnosis were divided into three main study groups: those who had
been recently diagnosed with a rheumatic disease, those who had a flare-up of the rheumatic disease, and those who had an infection in
the course of the rheumatic disease. Appropriate statistical tests and decision-tree analysis by R and ROC curve were applied. p < 0.05
was considered statistically significant.Results: A total of 2442 patients (311 (12.7%) with rheumatic disorders) were identified. Eightysix (27.7%) patients had newly diagnosed rheumatic disease (41; 47.7% with vasculitis); 111 (35.7%) had rheumatic disease flare-up (92;
82.9% with inflammatory arthritis); and 114 (36.6%) had coexisting infection (61; 53.5% inflammatory arthritis). Irrespective of the
study group, the most commonly encountered diseases were rheumatoid arthritis and spondyloarthritis. Serum albumin levels (2.78
mg/dL) and platelet count (290/mm6) were valuable to discriminate disease flare-up and coexisting infection; moreover, high ferritin
levels were accounted for adult-onset Still disease among patients with newly diagnosed rheumatic diseases.
Conclusion: Extremely high ESR is still a valuable clinical parameter, and rheumatic causes are significant besides malignancy and
infections. Albumin, thrombocyte count, and ferritin are other tests that clinicians should consider when caring for a patient with ESR
≥ 100 mm/h who has rheumatic disease.
Key words: Erythrocyte sedimentation rate, albumin, ferritin, thrombocyte

1. Introduction
Red blood cell descendence rate in uncoagulated venous
blood in a given period is defined as the erythrocyte
sedimentation rate (ESR) [1]. ESR is elevated in acute
tissue damage; infectious conditions such as cellulitis,
pneumonia, and soft tissue infections; rheumatic
diseases such as rheumatoid arthritis, ankylosing
spondylitis, vasculitis, systemic lupus erythematosus,
connective tissue disorders, and malignancies such as
lung cancer and lymphoma, as well as in physiological
processes like pregnancy [1]. Clinicians have long used
ESR to assess acute phase response. However, it has a
low sensitivity and specificity [2]. An ESR of ≥100 mm/h
generally indicates the presence of a severe underlying
disease.
In Fincher and Page’s study of 1006 patients, most
patients with ESR ≥ 100 mm/h had malignancy (33%),

rheumatic diseases (17%), and infection (14%) [3]. In
another large study of 4807 patients with an ESR ≥ 100
mm/h, 38% of the patients had autoimmune diseases with
the distribution as follows: rheumatoid arthritis was the
most common, polymyalgia rheumatica, systemic lupus
erythematosus, giant cell arteritis, and gout were the other
common rheumatic diseases [4]. The reasons for this
significant increase in ESR in patients with the rheumatic
disease could be due to the rheumatic disease itself, a
flare-up of the underlying disease, or infections added to
the clinical picture of the rheumatic diseases [5]. Hence,
the characteristics of these three conditions are not well
documented in the literature.
The objectives of the present study were to determine
the distribution of rheumatic diseases in patients with ESR
≥ 100 mm/h and to identify the factor which may aid in
discriminating study groups.

* Correspondence: dr.emrebilgin@gmail.com
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2. Materials and methods
2.1. Patients and study groups
In this descriptive study, charts of patients who applied
to Hacettepe University Medical Faculty Hospital with an
ESR ≥ 100 mm/h in the laboratory examination between
2015 and 2020 were reviewed. Patients with ESR ≥ 100
mm/h were divided into four diagnostic groups based
on etiology: infection (without a known rheumatic
diagnosis), oncologic (without a known rheumatic
diagnosis), rheumatic, and no definitive diagnosis. The
current study included patients with a definite rheumatic
disease with an ESR of ≥100 mm/h. Among patients with
rheumatic disorders, patients with missing demographic
or laboratory data (>50%) were also excluded from the
analysis.
The patients were divided into three main study
groups: those who had recently been diagnosed with
the rheumatic disease, those who developed the disease
flare-up of previously diagnosed rheumatic disease, and
those who had an infection during the follow-up of the
rheumatic disease. Inflammatory arthritis, vasculitis,
connective tissue diseases, and adult-onset Still disease
(AOSD) were the rheumatic disease subgroups. An
experienced rheumatologist reviewed the anamnesis,
laboratory, and imaging data of the patients to confirm the
newly diagnosed rheumatic diseases. Flare-up was defined
as the need for newly prescribed immunosuppressive
agents or increment of dose of the already prescribed
immunosuppressive agents and NOT prescription of any
antibiotics. Infection was defined as documentation of a
possible infective agent via culture or imaging findings
suggesting infection and prescription of any antibiotics.
Patients with known rheumatic disease, coexisting
malignancy, or any possible cause other than flare-up and
infection (heart failure, etc.) were excluded.
2.2. Data assessment
Demographic (age at ESR ≥ 100 mm/h and sex) and
laboratory data temporarily nearest to ESR ≥ 100 mm/h:
complete blood count with differentials, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
creatinine, alkaline phosphatase (ALP), albumin, total
protein, C-reactive protein (CRP), fibrinogen, ferritin,
iron, total iron-binding capacity (TIBC), gamma-glutamyl
transferase (GGT), mean red blood cell volume (MCV),
red blood cell distribution width (RDW) and mean platelet
volume (MPV), complement 3 (C3), complement 4 (C4),
total cholesterol, triglyceride, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and vitamin B12
levels were recorded.
2.3. Statistical analysis
IBM SPSS statistics version 25 (SPSS, Chicago, USA) was
used for the statistical analysis. Categorical variables were
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expressed as numbers with percentages. Continuous data
were presented as means (standard deviations) or medians
and (minimum–maximum) based on their distribution.
Chi-squared (post hoc Bonferroni correction) or Fisher’s
exact tests, where appropriate, were used for comparison
of groups for categorical variables. Intergroup differences
were assessed by using one-way ANOVA (post hoc Tukey
HSD) or the Kruskal–Wallis (post hoc Bonferroni) test for
the continuous data. A decision tree by R (package party)
was used to construct a clinician-friendly algorithm to
discriminate between disease flare-ups and infection by
using routine laboratory tests. Moreover, multivariable
logistic regression analysis was done to find factors
associated with infection over flare-up. Receiver operator
curve (ROC) analysis was done to find cut-off values
for relevant parameters, which can aid in differentiating
rheumatic disease subgroups among patients with newly
diagnosed rheumatic disorders. p < 0.05 was considered
statistically significant.
3. Results
A total of 2442 individual patients who applied to our
hospital between 2015 and 2020 and had ESR ≥ 100
mm/h were identified via the hospital database. Of these
2442 patients, 1257 were female (51.5%) and the median
(min–max) age was 58.8 (3–97) years. Distribution of the
main diagnostic groups was as follows: malignancy in
1061 (43.4%) patients [most common was lung cancer 136
(12.8%)], infection in 779 (31.9%) patients [most common
was pneumonia 156 (20.0%)], and rheumatic disorders
in 336 (13.8%) patients, and 266 (10.9%) patients did not
have a definite diagnosis. As 25 of the 336 patients with
rheumatic disorders had missing data, the remaining
311 patients constituted the main study group of these
analyses. As the main focus of this study is the ‘’rheumatic
perspective’’, no other result or discussion regarding the
other diagnostic groups will be given.
3.1. Distribution of rheumatic diagnoses among main
study groups
Of the 311 patients, 204 (65.5%) were female, with a mean
age of 52.0 (17.5) (min–max: 18-90). Eighty-six (27.7%)
patients had newly diagnosed rheumatic disease, 111
(35.7%) patients had rheumatic disease flare-up, and 114
(36.6%) patients had both rheumatic disease and infection.
Inflammatory arthritis was the most common in the entire
patient group (180 [57.9%]), followed by vasculitis (73
[23.5%]), connective tissue diseases (44 [14.1%]), and
Still disease (14 [4.5%]) (Table 1). In individual disease
perspective and irrespective of main study groups, the
most common diseases were as follows: rheumatoid
arthritis (96; 30.8%), spondyloarthritis (58; 18.7%),
large vessel vasculitis (including PMR) (39; 12.5%), and
systemic lupus erythematosus (22; 7.0%).
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Table 1. Distribution of patients with ESH ≥ 100 using rheumatic disease subgroups and individual rheumatic diagnoses grouped
according to main study group (N = 311).
Main study groups
All patients,
N = 311

Newly diagnosed
rheumatic diseases,
N = 86 (27.7%)

Rheumatic disease
activation,
N = 111 (35.7%)

Infection in rheumatic
diseases,
p-value
N = 114 (%36,6)

Female, N (%)

204 (65.5)

56 (65.1)

85 (76.6)

63 (55.3)

0.003*

Age, (mean (SD)), years

52.0 (17.5)

53.4 (17.7)

48.1 (17.5)

54.5 (16.7)

0.014**

Rheumatic
disease subgroups
Inflammatory arthritis

<0.001♣
180 (57.9)

27 (31.3)

92 (82.9)

61 (53.5)

Rheumatoid arthritis

96 (30.9)

13 (15.1)

56 (50.5)

27 (23.7)

Gout-crystal arthritis

13 (4.2)

5 (5.8)

2(1.8)

6 (5.3)

Spondyloarthritis

58 (18.7)

8 (9.3)

30 (27.0)

20 (17.5)

JIA

4 (1.3)

0

2 (1.8)

2 (1.8)

FMF

9 (2.9)

1 (1.2)

2 (1.8)

6 (5.3)

73 (23.5)

41 (47.7)

11 (9.9)

21 (18.4)

GVV & PMR

39 (12.5)

25 (29.1)

7 (6.3)

7 (6.1)

AAV

18 (5.8)

7 (8.1)

2 (1.8)

9 (7.9)

SMV

3 (1.0)

0

0

3 (2.7)

Polyarteritis nodosa

3 (1.0)

2 (2.3)

1 (0.9)

0

Behcet’s syndrome

3 (1.0)

1 (1.2)

1 (0.9)

1 (0.9)

Rheumatoid vasculitis

1 (0.3)

1 (1.2)

0

0

IgG4-related disease

5 (1.6)

5 (5.8)

0

0

Cerebral vasculitis

1 (0.3)

0

0

1 (0.9)

44 (14.1)

9 (10.5)

7 (6.3)

28 (24.5)

SLE

22 (7.0)

5 (5.8)

5 (4.5)

12 (10.5)

Systemic sclerosis

7 (2.2)

1 (1.2)

1 (0.9)

5 (4.4)

Sarcoidosis

5 (1.6)

2 (2.3)

0

3 (2.6)

Sjogren’s syndrome

3 (1.0)

0

0

3 (2.6)

Myositis

2 (0.6)

0

0

2 (1.8)

Overlap syndrome

1 (0.3)

0

1 (0.9)

0

Relapsing polychondritis

2 (0.6)

1 (1.2)

0

1 (0.9)

Retroperitoneal fibrosis

1 (0.3)

0

0

1 (0.9)

Granulomatous mastitis

1 (0.3)

0

0

1 (0.9)

14 (4.5)

9 (10.5)

1 (0.9)

4 (3.5)

Vasculitis & assoc. dis.

Connective tissue dis.

Adult still disease

<0.001*

<0.001*

<0.001*

0.03*

FMF: Familial mediterranean fever, AAV: ANCA-associated vasculitis, GVV: Great vessel vasculitis, JİA: Juvenile idiopathic arthritis,
SMV: Small vessel vasculitis, PMR: Polymyalgia rheumatica, SLE: Systemic lupus erythematosus.
Percentages are column percentages
♣
Corresponds to p-value of comparison of disease subgroups among main study groups
*p-value of chi-squared test from the comparison of each rheumatic disease subgroup frequencies between main study groups
Post hoc comparison for the source of difference (via Bonferroni correction):
Inflammatory arthritis: Rheumatic disease activation
Vasculitis & assoc. dis: Newly diagnosed rheumatic disorders
Connective tissue disorder: Infection in rheumatic diseases
Adult Still disease: Newly diagnosed rheumatic disorders
**p-value of one way analysis of variances. Difference was caused by rheumatic disease activation group (post hoc Tukey HSD).
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Vasculitis was the most common cause of ESR ≥
100 mm/h in patients diagnosed with a new rheumatic
disease (41; 47.7%), followed by inflammatory arthritis
(27; 31.3%), connective tissue diseases (9; 10.5%), and
adult Still disease (9; 10.5%) (Table 1). In disease flare-up
group, inflammatory arthritis (92; 82.9%) [rheumatoid
arthritis (56; 50.5%) and spondyloarthritis (30; 27.0%])
was the dominant diagnosis and other notable diseases
include large vessel vasculitis (7; 6.3%) and SLE (5;
4.5%). In the infection group, rheumatoid arthritis and
spondyloarthritis were the most common diseases,
just as they were in the disease flare-up group. Another
noteworthy point is that the study included a large
number of patients (28/44 (63.6%)) with connective tissue
disorders who had increased ESR due to infection during
follow-up.Evaluation of the laboratory parameters
3.1.1. Comparison of laboratory parameters between
study groups (new diagnosis, flare-up, and infection)
When the laboratory parameters were compared at the
group level, some differences existed among groups.
Patients in the infection group had higher neutrophil
counts, lower thrombocyte counts, higher MCV and
MPV, higher transaminase levels, lower creatinine, lower
albumin, and total protein levels, and higher CRP and B12
levels (Table 2). Patients with newly diagnosed rheumatic
diseases had lower HDL and ferritin levels than those in
the other groups.

To find variables that can be used to aid disease flareup and infection discrimination, we have performed a
decision-tree analysis (Figure 1). In this analysis, infection
was found in 89.1% of the patients and flare-up was found
in 10.9% when the serum albumin value was less than
2.78 g/dL. If the platelet count was less than 290,000/mm3,
infection was present in 69.2% of patients with a serum
albumin value greater than 2.78 g/dL, while flare-up was
present in 30.8%. If the serum albumin level is greater
than 2.78 g/dL and the platelet count is greater than
290,000/mm3, flare-up was diagnosed in 67.1% of patients,
and infection was diagnosed in 32.9%. In multivariable
analysis, these factors were associated with infection over
flare-up (reference level): thrombocyte count (per 1000/
mm3 increment) (aOR: 0.997 (0.995-0.999)), albumin (per
1 gr/dL increment) (aOR: 0.371 (0.218–0.630)), CRP (1
mg/dL increment) (aOR: 1.044 (1.011–1.044)).
3.1.2. Comparison of laboratory parameters in each study
group (new diagnosis, flare-up, and infection) according
to rheumatic disease subgroups (inflammatory arthritis,
vasculitis, connective tissue disorders, and adult Still
disease)
Of patients with newly diagnosed rheumatic disease,
patients with adult-Still disease had significantly higher
ferritin levels: adult Still group 808 (357–15000 µg/mL),
inflammatory arthritis 105 (14–795), vasculitis 171 (3–
653), and connective tissue diseases 154 (3–497) (p < 0.001)

Figure 1. Decision tree to discriminate patients with disease flare-up and coexisting
infection among patients with the rheumatic disease and ESR ≥ 100 mm/h.
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Table 2. Comparison of laboratory values between main study groups.
Main study groups
Variable

Newly diagnosed
rheumatic diseases
(n = 86)

Rheumatic disease
activation
(n = 111)

Infection in rheumatic
diseases
(n = 114)

P† value

Hemoglobin (mg/dL)

10.1 (1.5)

10.2 (1.3)

10.0 (1.5)

0.74

Anemia (<12)

80 (93.0)

101 (91.8)

102 (89.5)

0.66

Leukocyte (/mm6)

9.8 (3.3)

9.4 (3.9)

10.3 (4.3)

0.17

Leukocytosis (≥10,000)

35 (40.7)

37 (33.3)

55 (48.3)

0.07

Neutrophil(/mm )

6.9 (2.9)

6.5 (3.7)

7.8 (4.1)

0.036

Neutrophilia (≥6400)

43 (50.0)

45 (41.3)

66 (57.9)

0.046

Thrombocyte(/mm )

432 (168)

441 (178)

350 (152)

<0.001

Thrombocytosis (≥350)

60 (69.8)

73 (66.4)

50 (43.9)

<0.001

MCV

77.6 (7.8)

75.7 (9.5)

81.6 (8.9)

<0.001

RDW

17.2 (3.5)

17.5 (2.7)

17.2 (3.0)

0.67

MPV

7.6 (0.9)

7.6 (0.9)

8.0 (1.0)

0.004

N

N

N

6

6

AST (IU)

85

17 (7–107)

108

19 (9–125)

114

22.9 (8–133)

0.01

ALT (IU)

86

17 (3–165)

110

14 (5–230)

114

18 (4–232)

0.08

ALP (IU)

75

98 (45–658)

77

90 (34–335)

108

98.5 (35–746)

0.16

GGT (IU)

74

34.5 (11–485)

76

25 (2–525)

108

40.5 (9–388)

0.001

Creatinine (mg/dL)

85

0.7 (0.4–10)

108

0.7 (0.3–5.4)

114

0.7 (0.3–9.1)

0.02

Albumin (g/dL)

84

3.3 (0.5)

108

3.6 (0.6)

114

3.1 (0.7)

<0.001

Total Protein (g/dL)

83

7.0 (0.7)

107

7.2 (0.9)

114

6.7 (1.2)

<0.001

CRP (mg/dL)

86

10(0.3–32)

110

8 (0.2–45)

114

13 (0.5–51)

<0.001

Fibrinogen (mg/dL)

31

579 (151)

34

486 (187)

60

538 (189)

0.17

HDL

59

42.3 (17.0)

82

50.5 (14.4)

76

44.4 (19.2)

0.01

Triglyceride

59

118 (59–408)

84

110 (44–858)

82

138 (42–740)

0.07

B12

64

254 (74–1500)

85

245 (79–1500)

96

296(98–1500)

0.05

C3

45

140.0 (45.6)

25

128.1 (39.8)

56

124.1 (35.9)

0.14

C4

44

28.8 (14.6)

23

23.1 (8.2)

56

26.0 (10.7)

0.17

Ferritin (µg/mL)*

67

170 (3–15000)

77

31 (3–588)

97

167 (8–8597)

<0.001

AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, CRP: C-reactive protein, GGT: Gammaglutamyl transferase, MCV: Mean corpuscular volume, MPV: Mean platelet volume, RDW: Red Cell Distribution Width.
†
p-value calculated with one way ANOVA (post hoc Tukey HSD), if the variable was described by using mean (standard deviation)
(with chi-squared test (post hoc Bonferroni correction) if the variable was described using by n(%), with the Kruskal–Wallis (post hoc
Bonferroni HSD) test if the variable was described by using median (minimum–maximum).
As a result of post hoc tests (Tukey HSD or Bonferroni) in the variables in which a statistically significant difference was detected
between the groups, the groups that caused the difference were:
Group 1 vs. group 2: HDL
Group 1 vs. group 3: AST
Group 2 vs. group 3: neutrophil count, creatinine, GGT
Group 2 vs group 1 and 3: albumin, ferritin
Group 3 vs group 1 and 2: thrombocyte count, MCV, MPV, total protein, CRP, B12
Data were given as mean (standard deviation) or n(%), if otherwise specified. *median (minimum–maximum).

1893

ÖZSOY et al. / Turk J Med Sci
(Table 3). The ROC curve analysis revealed that it had an
89% sensitivity and 92% specificity for distinguishing
adult-onset Still disease from other rheumatic diseases
with the cut-off value of 440 µg/mL for ferritin (Figure 2)
(AUC: 0.97 (0.93–0.99), p < 0.001).
Among patients with disease flare-ups, complement
three levels were significantly lower in patients with
connective tissue disorders compared to inflammatory
arthritis and vasculitis groups (Table 4). Lastly, of patients
in the main infection group, patients with connective tissue
disorders were younger, had a higher likelihood of female
sex, and had higher MPV and RDW levels. Albumin levels
in patients with vasculitis were significantly lower than
in inflammatory arthritis and connective tissue disorders
groups; also, ALT, fibrinogen, and ferritin levels were
higher in patients with vasculitis than in these two groups
(Table 5).
4. Discussion
The present study evaluated 2442 patients with an ESR ≥
100 mm/h. Malignancy was the most common etiological
cause, accounting for 43.4% of all cases, followed by
infection (31.9%) and rheumatic diseases (13.8%). Patients
with rheumatic diseases can be divided into three main
study groups: new diagnosis, rheumatic disease flare-up,
and infections added to rheumatic disease. Vasculitis was
the most common cause in newly diagnosed patients,
while inflammatory arthritis was prominent in patients
with disease flare-ups. Inflammatory arthritis was in
the foreground in patients with rheumatic disease and
infection, while connective tissue diseases were another
critical group of patients in this regard. We hypothesized

that a diagnostic algorithm consisting of serum albumin
and platelets could be helpful in differentiating rheumatic
disease flare-ups and coexisting infections, which is an
important clinical problem.
Similar to the fever of unknown origin, patients with
ESR ≥ 100 mm/h fall into one of the three disease groups:
malignancies, infections, and inflammatory rheumatic
diseases. In our study, unlike the literature, malignancy
was encountered more frequently than infectious diseases
among the etiological causes. In the study of Otero-Castro
et al., which included 879 patients between 2002 and 2014,
infections were in the first line with 42%, malignancy in
the second line with 22%, and autoimmune-inflammatory
diseases in the third line with 13% [6]. In the study by
Lluberas-Acosta and Schumacher in hospitalized patients
with an ESR ≥ 100 mm/h, infections were the most
common etiological cause and rheumatic diseases the
second [7]. While malignancies and infectious diseases
were determined in the foreground in our study, since
our center is a reference center that serves especially
oncological patients in Turkey, inflammatory rheumatic
diseases occur significantly.
The literature generally provides a distribution of
patients with an ESR ≥ 100 mm/h. In our study, unlike
the literature, we proposed a new grouping perspective
for patients with rheumatic disease and ESR ≥ 100 mm/h,
which we believe is more appropriate for clinical settings.
In daily practice, these patients present with newly
diagnosed rheumatic diseases, rheumatic disease flareups, and rheumatic disease with infections. In line with
the prevalence of the disorders in general population,
inflammatory arthritides (mainly rheumatoid arthritis

Figure 2. ROC analysis for ferritin to discriminate adult-onset
Still disease from other rheumatic diseases in newly diagnosed
rheumatic disease study group (AUC: 0.97 (0.93–0.99), p < 0.001).
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N

9.1 (4.7–18.6)

6.9 (2.1–16.1)

466 (157–1248)

80.0 (58.1–89.5)

16.3 (12.7–26.8)

7.4 (6.3–9.2)

N

Leukocyte (/mm6)

Neutrophil (/mm )

Thrombocyte(/mm6)

MCV

RDW

MPV

27

20

21

27

27

26

27

6

18

18

21

8

8

17

ALT (IU)

ALP (IU)

GGT (IU)

Creatinine (mg/dL)

Albumin (g/dL)

Total protein (g/dL)

CRP (mg/dL)

Fibrinogen (mg/dL)

HDL

Triglyceride

B12

C3

C4

Ferritin (µg/mL)

105 (14–795)

32 (5–43)

148 (107–237)

266 (109–1081)

103 (59–408)

40 (22–64)

581 (225–759)

10.4 (1.5–31.0)

7.0 (5.3–8.2)

3.3 (2.4–4.7)

0.6 (0.4–1.4)

45.0 (11.0–383.0)

97.0 (45.0–658.0)

16.0 (5.0–60.0)

33

24

24

41

26

26

14

41

49

40

41

37

39

41

41

171 (3–653)

29 (2–67)

150 (38–222)

235 (74–717)

118 (62–272)

43 (20–113)

629 (270–891)

10.7 (1.6–32.0)

7.2 (5.4–8.4)

3.2 (1.0–4.4)

0.7 (0.4–10.4)

35.0 (11.0–206.0)

104.0 (63.0–354.0)

17.0 (3.0–80.0)

16.0 (8.0–50.0)

17.0 (13.1–32.2)

78.5 (62.6–88.3)

442 (166–882)

6.2 (3.1–14.7)

9.7 (5.1–18.3)

9.9 (7.3–15.3)

59 (18–77)

8

6

6

9

7

6

5

9

9

9

8

8

8

9

9

N

154 (3–497)

19 (7–39)

90 (42–152)

266 (162–1500)

141 (70–335)

44 (30–56)

616 (476–793)

8.7 (0.3–17.7)

6.8 (5.7–8.7)

3.3 (3.0–3.9)

0.6 (0.4–2.8)

15.5 (12.0–211.0)

66.0 (59.0–272.0)

19.0 (5.0–37.0)

16.0 (10.0–47.0)

8.2 (6.2–9.3)

17.4 (14.1–27.8)

77.2 (62.1–91.4)

301 (245–531)

5.6 (2.8–9.1)

8.6 (4.3–19.4)

9.5 (8.1–11.9)

56 (32–79)

5 (55.6)

Connective tissue disorders
n=9

Data were given as median (minimum–maximum)) or n(%), if otherwise specified.*The Kruskal–Wallis test, ** Chi-squared test.

26

AST (IU)

17.5 (7.0–107.0)

7.8 (5.0–9.3)

9.9 (7.2–15.6)

Hemoglobin (mg/dL)

6

58 (20–80)

Age

28 (68.3)

17 (63.0)

Female, n(%)

Vasculitis
n = 41

Inflammatory arthritis
n = 27

Variable

9

6

7

3

8

9

6

9

8

8

9

8

8

9

9

N

808 (357–15000)

27 (10–69)

167 (76–216)

252 (187–571)

180 (84–265)

29 (20–60)

523 (390–616)

8.4 (4.3–26.0)

7.3 (6.1–8.1)

3.2 (2.8–4.2)

0.7 (0.5–0.8)

53.0 (16.0–485.0)

134.0 (61.0–326.0)

28.0 (8.0–165.0)

44.0 (20.0–63.0)

7.8 (6.7–8.9)

16.8 (7.2–22.7)

78.2 (57.2–87.5)

372 (110–639)

7.4 (3.0–10.3)

9.0 (5.6–13.3)

10.1 (7.5–11.7)

52 (19–69)

6 (66.7)

Adult Still disease
n=9

Table 3. Comparison of laboratory tests according to rheumatic disease subgroups in patients newly diagnosed with rheumatic disease.

<0.001

0.45

0.09

0.88

0.39

0.18

0.47

0.43

0.48

0.76

0.32

0.29

0.26

0.26

0.08

0.78

0.64

0.99

0.09

0.45

0.66

0.74

0.68

0.89**

p*
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1896
N

5.7 (0.7–27.6)

402 (78–1228)

76.3 (57.3–96.1)

17.1 (11.0–28.5)

7.6 (5.8–9.9)

N

Neutrophil (/mm6)

Thrombocyte (/mm )

MCV

RDW

MPV

91

61

60

89

89

88

91

26

68

70

70

15

13

61

ALT (IU)

ALP (IU)

GGT (IU)

Creatinine (mg/dL)

Albumin (g/dL)

Total protein (g/dL)

CRP (mg/dL)

Fibrinogen (mg/dL)

HDL

Triglyceride

B12

C3

C4

Ferritin (µg/mL)
31 (3–588)

23 (17–44)

136 (69–209)

246 (87–1500)

113 (44–363)

51 (22–91)

489 (182–910)

8.1 (0.2–45.4)

7.3 (5.9–9.3)

3.6 (2.5–7.0)

0.7 (0.3–5.4)

25.5 (2.0–525.0)

93 (24–274)

14.0 (5.0–230.0)

9

4

4

10

10

10

6

11

11

11

11

10

10

11

11

28 (8–285)

23 (19–31)

166 (116–191)

250 (158–384)

80 (50–858)

46 (18–70)

560 (296–747)

9.2 (0.4–34.4)

6.9 (5.6–8.3)

3.5 (2.6–4.1)

0.7 (0.4–0.9)

20.0 (9.0–275.0)

89 (51–335)

11.0 (6.0–51.0)

16.0 (10.0–60.0)

17.1 (14.0–20.8)

78.5 (59.0–96.3)

418 (311–904)

6.3 (2.3–9.9)

8.2 (4.5–14.0)

9.4 (7.3–12.0)

33 (19–79)

6

6

6

5

4

4

1

7

7

7

7

6

6

7

7

N

8.0 (7.4–9.2)

23 (9–160)

16 (8–28)

84 (61–130)

243 (79–746)

168 (88–221)

61 (45–65)

241

3.0 (0.2–24.0)

7.4 (6.5–8.0)

3.5 (3.0–3.9)

0.6 (0.5–0.8)

22.5 (10.0–69.0)

87 (50–175)

16.0 (11.0–38.0)

24.0 (9.0–76.0)

17.4 (14.0–22.6)

72.6 (58.0–79.3)

327 (291–649)

6.3 (3.0–8.9)

8.3 (5.3–10.5)

10.6 (9.6–11.9)

42 (21–65)

8 (85.7)

Connective tissue disorders
n=7

Data were given as median (minimum–maximum)) or n(%), if otherwise specified.*The Kruskal–Wallis test, ** Chi-squares test.

89

AST (IU)
19.0 (9.0–125.0)

7.6 (6.4–10.7)

8.8 (3.8–31.0)

Leukocyte (/mm )

6

10.1 (7.1–14.4)

Hemoglobin (mg/dL)

6

49 (18–90)

Age

8 (72.7)

70 (76.1)

Female, n(%)

Vasculitis
n = 11

Inflammatory arthritis
n = 92

Variable

0.86

0.29

0.032

0.93

0.13

0.27

0.30

0.30

0.26

0.44

0.98

0.76

0.91

0.41

0.23

0.18

0.92

0.24

0.36

0.88

0.49

0.09

0.42

0.81**

p*

Table 4. Comparison of laboratory tests according to rheumatic disease subgroups in patients presenting with flare-up of rheumatic disease (The adult Still group was not included
in the analysis because of only 1 patient).
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N

8.0 (0–21.0)

345 (114–878)

84.1 (58.2–101.0)

16.6 (13.3–25.6)

7.9 (5.9–10.0)

N

Neutrophil (/mm6)

Thrombocyte (/mm )

MCV

RDW

MPV

61

56

56

61

61

61

61

32

39

43

51

20

20

48

ALT (IU)

ALP (IU)

GGT (IU)

Creatinine (mg/dL)

Albumin (g/dL)

Total protein (g/dL)

CRP (mg/dL)

Fibrinogen (mg/dL)

HDL

Triglyceride

B12

C3

C4

Ferritin (µg/mL)
159 (14–2334)

28 (3–38)

125 (48–216)

289 (98–1500)

129 (42–382)

43 (17–87)

486 (250–944)

13.5 (0.6–46.0)

6.9 (3.5–9.1)

3.2 (1.3–5.3)

0.7 (0.3–8.2)

39 (10–195)

97 (35–440)

15.0 (4.0–139.0)

19

11

11

18

14

14

13

21

21

21

21

21

21

21

21

355 (25–3010)

31 (17–53)

136 (99–156)

339 (104–916)

134 (70–585)

32 (17–83)

561 (501–930)

15.0 (3.8–37.1)

6.7 (5.2–8.1)

2.9 (2.1–3.8)

0.9 (0.4–9.2)

57 (17–320)

103 (60–325)

28.0 (7.0–232.0)

26.0 (9.0–110.0)

15.6 (13.1–33.6)

83.0 (67.9–95.8)

323 (134–876)

7.5 (1.3–23.3)

10.1 (2.8–25.7)

10.0 (7.0–12.1)

62 (33–82)

26

22

22

25

24

22

13

28

28

28

28

27

27

28

28

N

106 (8–3020)

19 (10–47)

122 (41–209)

265 (110–949)

153 (67–740)

37 (19–93)

516 (286–638)

12.5 (0.5–50.6)

6.5 (5.2–8.6)

3.3 (1.8–4.7)

0.6 (0.4–8.3)

38 (9–388)

92 (48–746)

18.5 (4.0–67.0)

19.5 (10.0–106.0)

8.3 (6.4–10.8)

17.5 (13.7–26.6)

77.3 (61.9–94.8)

330 (72–703)

6.0 (0–14.1)

8.6 (0.1–17.7)

9.8 (7.5–12.4)

48 (18–77)

22 (78.6)

Connective tissue disorders
n = 28

Data were given as median (minimum–maximum)) or n(%), if otherwise specified.* The Kruskal–Wallis test, ** Chi-squared test.

61

AST (IU)
20.0 (8.0–133.0)

7.4 (5.8–9.0)

10.8 (1.6–23.0)

Leukocyte (/mm )

6

10.0 (7.1–13.9)

Hemoglobin (mg/dL)

6

59 (19–88)

Age

5 (23.8)

33 (54.1)

Female, n(%)

Vasculitis
n = 21

Inflammatory arthritis
n = 61

Variable

Table 5. Comparison of laboratory tests according to rheumatic disease subgroups in patients presenting with infection
(The adult Still group was not included because of only 1 patient).

0.015

0.17

0.70

0.66

0.14

0.59

0.036

0.30

0.61

0.032

0.08

0.16

0.61

0.023

0.28

0.018

0.028

0.05

0.27

0.26

0.19

0.60

0.03

0.01**

p*
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(RA) and spondyloarthritis (SpA)) were the most
common diseases among all patients. In a recent study by
Daniels et al. from the Mayo clinic, RA was found to be
the prominent disease [4]. On the other hand, vasculitis
and related diseases came to the fore in the newly
diagnosed rheumatic diseases group. In this respect, large
vessel vasculitis and, less frequently, ANCA-associated
vasculitis were the diseases that should always be kept
in mind. Inflammatory arthritis was the most prominent
cause, especially in the group of patients with rheumatic
disease flare-ups, approximately 83% of all exacerbations
were associated with inflammatory arthritis, especially
RA.
Two conditions are considered in the foreground if a
patient with known rheumatic disease is admitted with
ESR ≥ 100 mm/h. The first is a flare-up of the existing
disease, and the second is the coexisting infections,
possibly due to the immunosuppressive drugs used. It is
important to distinguish between these two conditions
because the treatment approaches are entirely different.
As the prevalence of the diseases is higher, we found
more RA and SpA patients with infections; however,
infections were also common in patients with systemic
lupus erythematosus and ANCA-associated vasculitis.
Even though connective tissue disorders are relatively
uncommon conditions, it should be noted that they can
be complicated by infections and result in an ESR ≥ 100
mm/h. On the other hand, we have also investigated
whether simple laboratory tests can be directive in daily
practice. From this point of view, two laboratory tests
come to the fore in patients with ESR ≥ 100 mm/h:
albumin and thrombocyte count. Albumin is a wellknown negative acute phase reactant. A mean value of 3.3
g/dL was observed in newly diagnosed rheumatic diseases.
Although this value is lower than normal, it corresponds
to a mild hypoalbuminemia. In the rheumatic disease
flare-up group, albumin levels were at the lower limit of
normal (mean 3.6 g/dL). On the other hand, when the
infection is added to the rheumatic disease, the mean
albumin levels reach a lower level than the other groups.
In the decision-tree analysis, it was seen that albumin
could be very valuable in differentiating exacerbation and
infection, with the cut-off value of albumin as 2.78 g/dL.
In addition, thrombocytosis was more prominent in the
flare-up group, while it was less frequent in infectious
diseases (66% vs. 44%). With all these results, a decrease
in albumin below 2.78 g/dL should suggest infections
rather than flare in the patient group with ESR >100. In
the presence of albumin levels above 2.78 g/dL, a platelet
count of 290,000/mm3 and above supports flare-up. This
diagnostic algorithm may be simple and instructive for
the clinician but should be supported by other studies.
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Adult Still disease was considered a separate rheumatic
disease subgroup in the study as the disease has unique
features. Especially among newly diagnosed rheumatic
diseases, AOSD has a prominent seat. One of the points
that make AOSD different is the high ferritin levels, which
are more prominent than in other groups. As a matter of
fact, in a previous study by us, it was determined that a
serum ferritin level more than five times of the normal
level with arthralgia is highly indicative of adult Still
disease [8]. Similarly, Ushiyama et al. reported that serum
ferritin levels higher than five times the normal levels have
a sensitivity of 74.8% and a specificity of 83.2% for adult
Still disease [9]. In the light of this information, it can be
said that the high ferritin level in the patient group with
ESR > 100 should put adult Still disease in the foreground.
The most important limitation of our study is that it
was a chart review. All possible inborn biases of this kind
of study can be applied to our research. On the other
hand, our study has several strengths. We followed a strict
inclusion-exclusion strategy. Moreover, our study contains
valuable data as it can lead to prospective long-term
follow-up studies.
In conclusion, high ESR still maintains its value in the
diagnostic process. Among patients with ESR ≥ 100 mm/h,
rheumatic diseases are the most critical etiologic causes
besides malignancy and infection. Coexisting infection
was the most common cause of ESR ≥ 100 mm/h in
patients with rheumatic diseases, followed by disease flareups. When biochemical parameters were evaluated, serum
ferritin levels in newly diagnosed rheumatic diseases
indicated adult-onset Still disease. Serum albumin levels
and thrombocyte counts may play a role in discriminating
rheumatic disease flare-ups from coexisting infections.
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